Question special

While impressive that 63% of patients lost greater than 5% of their weight over the course of 56 weeks in this trial, liraglutide 3.0's prescribing information recommends that it be discontinued at 16 weeks if the patient has not lost 4% or more body weight. In this trial, what percentage of subjects taking the medication at 16 weeks had lost 4% of their weight? (Hard to interpret this from Figure 1A). What was the evidence that supported inclusion of this 4% cutoff in the prescribing instructions?